ESR1 and breast carcinoma: As expected from other recent studies [17,58,59] and consistent with the tenet that more epithelial-like ER+ breast cancers progress more slowly, we found that the epithelial-like miR-200c-competent cells express more antigen-presenting molecules, which provides more potential T cell targets than the mesenchymal counterparts.